Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8930760,flow-rate,"At a flow-rate of 1 ml/min, a concentration gradient is applied.",Determination of mivacurium in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930760/),[ml] / [min],1,2484,DB01226,Mivacurium
,8930760,detection limit,The detection limit is approximately 1 ng/ml in plasma.,Determination of mivacurium in plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930760/),[ng] / [ml],1,2485,DB01226,Mivacurium
,14580052,infusion rates,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),[μg] / [kg·min],3.0,2929,DB01226,Mivacurium
,14580052,infusion rates,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),[μg] / [kg·min],3.6,2930,DB01226,Mivacurium
,14580052,train-of-four ratio,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),min,21.9,2931,DB01226,Mivacurium
,14580052,train-of-four ratio,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),min,17.9,2932,DB01226,Mivacurium
,10839906,time to first response,"The time to first response to train-of-four nerve stimulation was 15 min (range, 9-21 min) and 59 min (range, 32-179 min) in patients receiving placebo and bambuterol, respectively.",The influence of drug-induced low plasma cholinesterase activity on the pharmacokinetics and pharmacodynamics of mivacurium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839906/),min,15,20800,DB01226,Mivacurium
,10839906,time to first response,"The time to first response to train-of-four nerve stimulation was 15 min (range, 9-21 min) and 59 min (range, 32-179 min) in patients receiving placebo and bambuterol, respectively.",The influence of drug-induced low plasma cholinesterase activity on the pharmacokinetics and pharmacodynamics of mivacurium. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10839906/),min,59,20801,DB01226,Mivacurium
,10490070,volume of distribution,"For the trans-trans isomer, mean +/- SEM volume of distribution was 0.18+/-0.024 L/kg, median half-life was 34.9 minutes (range, 26.7 to 53.5 minutes), and clearance was 12+/-2 ml/min/kg.",Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490070/),[l] / [kg],0.18,47744,DB01226,Mivacurium
,10490070,half-life,"For the trans-trans isomer, mean +/- SEM volume of distribution was 0.18+/-0.024 L/kg, median half-life was 34.9 minutes (range, 26.7 to 53.5 minutes), and clearance was 12+/-2 ml/min/kg.",Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490070/),min,34.9,47745,DB01226,Mivacurium
,10490070,clearance,"For the trans-trans isomer, mean +/- SEM volume of distribution was 0.18+/-0.024 L/kg, median half-life was 34.9 minutes (range, 26.7 to 53.5 minutes), and clearance was 12+/-2 ml/min/kg.",Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10490070/),[ml] / [kg·min],12,47746,DB01226,Mivacurium
,9305559,%,The mean mivacurium infusion requirement to maintain 97 +/- 1 (mean +/- SD)% depression of the twitch response was 6.0 +/- 0.4 micrograms.,Prolonged mivacurium infusion in young and elderly adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9305559/),μ,6,67591,DB01226,Mivacurium
,9305559,infusion requirement,The infusion requirement in patients with low plasma cholinesterase activity was the lowest 2.4 +/- 1.2 micrograms.,Prolonged mivacurium infusion in young and elderly adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9305559/),μ,2.,67592,DB01226,Mivacurium
,9054251,elimination half-lives,"Mean elimination half-lives of the trans-trans, cis-trans, and cis-cis isomers were 2.4, 2, and 28.5 min, respectively, with corresponding mean plasma clearances of 29.2, 45.7, and 6.7 ml.min 1.kg-1.",Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054251/),min,2.4,99765,DB01226,Mivacurium
,9054251,elimination half-lives,"Mean elimination half-lives of the trans-trans, cis-trans, and cis-cis isomers were 2.4, 2, and 28.5 min, respectively, with corresponding mean plasma clearances of 29.2, 45.7, and 6.7 ml.min 1.kg-1.",Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054251/),min,2,99766,DB01226,Mivacurium
,9054251,elimination half-lives,"Mean elimination half-lives of the trans-trans, cis-trans, and cis-cis isomers were 2.4, 2, and 28.5 min, respectively, with corresponding mean plasma clearances of 29.2, 45.7, and 6.7 ml.min 1.kg-1.",Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054251/),min,28.5,99767,DB01226,Mivacurium
,9054251,plasma clearances,"Mean elimination half-lives of the trans-trans, cis-trans, and cis-cis isomers were 2.4, 2, and 28.5 min, respectively, with corresponding mean plasma clearances of 29.2, 45.7, and 6.7 ml.min 1.kg-1.",Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054251/),[1·min·ml] / [kg],29.2,99768,DB01226,Mivacurium
,9054251,plasma clearances,"Mean elimination half-lives of the trans-trans, cis-trans, and cis-cis isomers were 2.4, 2, and 28.5 min, respectively, with corresponding mean plasma clearances of 29.2, 45.7, and 6.7 ml.min 1.kg-1.",Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054251/),[1·min·ml] / [kg],45.7,99769,DB01226,Mivacurium
,9054251,plasma clearances,"Mean elimination half-lives of the trans-trans, cis-trans, and cis-cis isomers were 2.4, 2, and 28.5 min, respectively, with corresponding mean plasma clearances of 29.2, 45.7, and 6.7 ml.min 1.kg-1.",Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054251/),[1·min·ml] / [kg],6.7,99770,DB01226,Mivacurium
,9054251,volumes of distribution at steady state,"The volumes of distribution at steady state of the trans-trans, cis-trans, and cis-cis isomers were 0.047, 0.054, and 0.189 l/kg, respectively.",Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054251/),[l] / [kg],0.047,99771,DB01226,Mivacurium
,9054251,volumes of distribution at steady state,"The volumes of distribution at steady state of the trans-trans, cis-trans, and cis-cis isomers were 0.047, 0.054, and 0.189 l/kg, respectively.",Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054251/),[l] / [kg],0.054,99772,DB01226,Mivacurium
,9054251,volumes of distribution at steady state,"The volumes of distribution at steady state of the trans-trans, cis-trans, and cis-cis isomers were 0.047, 0.054, and 0.189 l/kg, respectively.",Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054251/),[l] / [kg],0.189,99773,DB01226,Mivacurium
,9054251,half-lives,"Plasma concentrations of monoester and alcohol metabolites peaked 25 s (median) after mivacurium injection, with half-lives in the range of 90 min, except for the cis alcohol metabolite, which was only negligibly and transiently formed.",Pharmacokinetics of mivacurium isomers and their metabolites in healthy volunteers after intravenous bolus administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054251/),min,90,99774,DB01226,Mivacurium
less,8010476,half-lives,These isomers differ in potency (the trans-trans and the cis-trans isomers are equipotent and the cis-cis isomer is 1/13th as potent a neuromuscular blocking agent) and in rates of in vitro hydrolysis (in vitro half-lives are less than 2 min for the cis-trans and trans-trans isomers and 276 min for the cis-cis isomer).,The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,2,104337,DB01226,Mivacurium
,8010476,half-lives,These isomers differ in potency (the trans-trans and the cis-trans isomers are equipotent and the cis-cis isomer is 1/13th as potent a neuromuscular blocking agent) and in rates of in vitro hydrolysis (in vitro half-lives are less than 2 min for the cis-trans and trans-trans isomers and 276 min for the cis-cis isomer).,The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,276,104338,DB01226,Mivacurium
,8010476,25-75%,"After discontinuation of the infusion, patients returned to 25% of their baseline muscle strength in 9.3 +/- 3.7 min and had 25-75% and 5-95% recovery indexes of 7.2 +/- 1.8 and 16.8 +/- 3.7 min, respectively.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,7.2,104339,DB01226,Mivacurium
,8010476,5-95% recovery indexes,"After discontinuation of the infusion, patients returned to 25% of their baseline muscle strength in 9.3 +/- 3.7 min and had 25-75% and 5-95% recovery indexes of 7.2 +/- 1.8 and 16.8 +/- 3.7 min, respectively.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,16.8,104340,DB01226,Mivacurium
,8010476,volumes of distribution (V beta),"The volumes of distribution (V beta) of the cis-trans, trans-trans, and cis-cis isomers were 0.29 +/- 0.24, 0.15 +/- 0.05, and 0.34 +/- 0.08 l/kg, respectively.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[l] / [kg],0.29,104341,DB01226,Mivacurium
,8010476,volumes of distribution (V beta),"The volumes of distribution (V beta) of the cis-trans, trans-trans, and cis-cis isomers were 0.29 +/- 0.24, 0.15 +/- 0.05, and 0.34 +/- 0.08 l/kg, respectively.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[l] / [kg],0.15,104342,DB01226,Mivacurium
,8010476,volumes of distribution (V beta),"The volumes of distribution (V beta) of the cis-trans, trans-trans, and cis-cis isomers were 0.29 +/- 0.24, 0.15 +/- 0.05, and 0.34 +/- 0.08 l/kg, respectively.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[l] / [kg],0.34,104343,DB01226,Mivacurium
,8010476,steady-state clearances,"kg-1.min-1 infusion, the steady-state clearances of the potent cis-trans and trans-trans isomers were 106 +/- 67 and 63 +/- 34 ml.min-1.kg-1, respectively; the clearance of the less potent cis-cis isomer was 4.6 +/- 1.1 ml.min-1.kg-1.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[ml] / [kg·min],106,104344,DB01226,Mivacurium
,8010476,steady-state clearances,"kg-1.min-1 infusion, the steady-state clearances of the potent cis-trans and trans-trans isomers were 106 +/- 67 and 63 +/- 34 ml.min-1.kg-1, respectively; the clearance of the less potent cis-cis isomer was 4.6 +/- 1.1 ml.min-1.kg-1.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[ml] / [kg·min],63,104345,DB01226,Mivacurium
,8010476,clearance,"kg-1.min-1 infusion, the steady-state clearances of the potent cis-trans and trans-trans isomers were 106 +/- 67 and 63 +/- 34 ml.min-1.kg-1, respectively; the clearance of the less potent cis-cis isomer was 4.6 +/- 1.1 ml.min-1.kg-1.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),[ml] / [kg·min],4.6,104346,DB01226,Mivacurium
,8010476,elimination half-lives,"The elimination half-lives of the cis-trans and trans-trans isomers were 1.8 +/- 1.1 and 1.9 +/- 0.7 min, respectively, and that of the cis-cis isomer was 52.9 +/- 19.8 min.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,1.8,104347,DB01226,Mivacurium
,8010476,elimination half-lives,"The elimination half-lives of the cis-trans and trans-trans isomers were 1.8 +/- 1.1 and 1.9 +/- 0.7 min, respectively, and that of the cis-cis isomer was 52.9 +/- 19.8 min.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,1.9,104348,DB01226,Mivacurium
,8010476,elimination half-lives,"The elimination half-lives of the cis-trans and trans-trans isomers were 1.8 +/- 1.1 and 1.9 +/- 0.7 min, respectively, and that of the cis-cis isomer was 52.9 +/- 19.8 min.",The pharmacokinetics and pharmacodynamics of the stereoisomers of mivacurium in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8010476/),min,52.9,104349,DB01226,Mivacurium
,15915024,Time to a train-of-four ratio,Time to a train-of-four ratio of 0.8 ranged from 30 to 60 min (n = 6).,Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915024/),min,0,107311,DB01226,Mivacurium
,15915024,Time to a train-of-four ratio,Time to a train-of-four ratio of 0.8 ranged from 30 to 60 min (n = 6).,Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915024/),min,30 to 60,107312,DB01226,Mivacurium
,15915024,train-of-four ratio,"Neostigmine injected after cholinesterase shortened recovery further, and a train-of-four ratio of 0.8 was reached in 10-30 min.",Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically homozygous for the atypical plasma cholinesterase variant: effect of injection of human cholinesterase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15915024/),,0.8,107313,DB01226,Mivacurium
,12027844,onset time,"The onset time was 1.4 min (0.8-1.9) median (range) and 1.3 min (1.1-1.9) and the time to first response to TOF nerve stimulation was 9.6 min (6.5-12.6) and 10.5 min (7.0-14.0) in young and older children, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),min,1.4,107643,DB01226,Mivacurium
,12027844,onset time,"The onset time was 1.4 min (0.8-1.9) median (range) and 1.3 min (1.1-1.9) and the time to first response to TOF nerve stimulation was 9.6 min (6.5-12.6) and 10.5 min (7.0-14.0) in young and older children, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),min,1.3,107644,DB01226,Mivacurium
,12027844,time to first response,"The onset time was 1.4 min (0.8-1.9) median (range) and 1.3 min (1.1-1.9) and the time to first response to TOF nerve stimulation was 9.6 min (6.5-12.6) and 10.5 min (7.0-14.0) in young and older children, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),min,9.6,107645,DB01226,Mivacurium
,12027844,time to first response,"The onset time was 1.4 min (0.8-1.9) median (range) and 1.3 min (1.1-1.9) and the time to first response to TOF nerve stimulation was 9.6 min (6.5-12.6) and 10.5 min (7.0-14.0) in young and older children, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),min,10.5,107646,DB01226,Mivacurium
,12027844,clearances,"The median clearances of the cis-cis, the cis-trans, and the trans-trans isomer were 5.5, 51.0 and 30.5 ml/kg/min, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),[ml] / [kg·min],5.5,107647,DB01226,Mivacurium
,12027844,clearances,"The median clearances of the cis-cis, the cis-trans, and the trans-trans isomer were 5.5, 51.0 and 30.5 ml/kg/min, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),[ml] / [kg·min],51.0,107648,DB01226,Mivacurium
,12027844,clearances,"The median clearances of the cis-cis, the cis-trans, and the trans-trans isomer were 5.5, 51.0 and 30.5 ml/kg/min, respectively.",The pharmacodynamics and pharmacokinetics of mivacurium in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12027844/),[ml] / [kg·min],30.5,107649,DB01226,Mivacurium
,12059892,ED95,"The estimated ED95 were 0.053 and 0.061 mg/kg in young adults and elderly patients, respectively (NS).",Pharmacokinetics and pharmacodynamics of mivacurium in young adult and elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12059892/),[mg] / [kg],0.053,109220,DB01226,Mivacurium
,12059892,ED95,"The estimated ED95 were 0.053 and 0.061 mg/kg in young adults and elderly patients, respectively (NS).",Pharmacokinetics and pharmacodynamics of mivacurium in young adult and elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12059892/),[mg] / [kg],0.061,109221,DB01226,Mivacurium
,12059892,duration to a TOF ratio,"The median infusion rate did not differ, but duration to a TOF ratio of 0.7 was significantly longer in elderly patients than in young adult patients (21.0 vs. 16.5 min).",Pharmacokinetics and pharmacodynamics of mivacurium in young adult and elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12059892/),min,0.7,109222,DB01226,Mivacurium
,12059892,duration to a TOF ratio,"The median infusion rate did not differ, but duration to a TOF ratio of 0.7 was significantly longer in elderly patients than in young adult patients (21.0 vs. 16.5 min).",Pharmacokinetics and pharmacodynamics of mivacurium in young adult and elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12059892/),min,21.0,109223,DB01226,Mivacurium
,12059892,duration to a TOF ratio,"The median infusion rate did not differ, but duration to a TOF ratio of 0.7 was significantly longer in elderly patients than in young adult patients (21.0 vs. 16.5 min).",Pharmacokinetics and pharmacodynamics of mivacurium in young adult and elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12059892/),min,16.5,109224,DB01226,Mivacurium
,7734267,T1,"After an initial bolus, mivacurium was administered continuously to maintain a T1 of 5 (4)% of baseline.",Effect of renal function on neuromuscular block induced by continuous infusion of mivacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7734267/),%,5,110083,DB01226,Mivacurium
,7669465,T1/T0,"Mivacurium chloride was infused at a rate of 15 micrograms kg-1 min-1 for 10 min, 7.5 micrograms kg-1 min-1 for a further 10 min, and then at a rate adjusted to maintain T1/T0 at 5%.","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),%,5,119905,DB01226,Mivacurium
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],2.4,119906,DB01226,Mivacurium
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],2.1,119907,DB01226,Mivacurium
,7669465,Clearance,"Clearance of the cis-cis isomer was reduced significantly in the renal failure (median 2.4 (range 2.1-2.6) ml kg-1 min-1) and intermediate renal function groups (2.1 (2.0-2.9) ml kg-1 min-1), compared with healthy patients (3.8 (2.6-4.9) ml kg-1 min-1) (P < 0.01 in each case).","Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7669465/),[ml] / [kg·min],3.8,119908,DB01226,Mivacurium
,9040105,apparent volume of distribution at steady-state,"The estimates of the apparent volume of distribution at steady-state and plasma clearance [mean(SE)] were 650 (123) mL kg-1 and 9.9 (0.75) mL min-1 kg-1, respectively.",Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040105/),[ml] / [kg],650,142149,DB01226,Mivacurium
,9040105,plasma clearance,"The estimates of the apparent volume of distribution at steady-state and plasma clearance [mean(SE)] were 650 (123) mL kg-1 and 9.9 (0.75) mL min-1 kg-1, respectively.",Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040105/),[ml] / [kg·min],9.9,142150,DB01226,Mivacurium
,9040105,Cess50 (,The estimate [mean(SE)] of Cess50 (steady-state plasma concentration eliciting half of maximum E) was 0.65 (0.01) microgram mL-1.,Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040105/),[μg] / [ml],0.65,142151,DB01226,Mivacurium
,9040105,steady-state plasma concentration eliciting half of maximum E),The estimate [mean(SE)] of Cess50 (steady-state plasma concentration eliciting half of maximum E) was 0.65 (0.01) microgram mL-1.,Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040105/),[μg] / [ml],0.65,142152,DB01226,Mivacurium
,9040105,Keo,The value [mean-(SE)] of Keo (rate constant of equilibration between plasma and effect site) was estimated at 0.32 (0.03) min-1.,Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040105/),1/[min],0.32,142153,DB01226,Mivacurium
,9040105,rate constant,The value [mean-(SE)] of Keo (rate constant of equilibration between plasma and effect site) was estimated at 0.32 (0.03) min-1.,Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040105/),1/[min],0.32,142154,DB01226,Mivacurium
,9040105,C50 (,The estimate [mean(SE)] of C50 (post-infusion C eliciting half of maximum E) was 0.57(0.03) microgram mL-1.,Pharmacokinetic-pharmacodynamic modeling of mivacurium in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9040105/),[μg] / [ml],0.57,142155,DB01226,Mivacurium
,1334687,"time to recovery of 25% neuromuscular transmission, T25","The mean time to recovery of 25% neuromuscular transmission, T25, was greater in the patients with liver failure (57.2 min) than in control patients (18.7 min).",Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1334687/),min,57.2,185052,DB01226,Mivacurium
,1334687,"time to recovery of 25% neuromuscular transmission, T25","The mean time to recovery of 25% neuromuscular transmission, T25, was greater in the patients with liver failure (57.2 min) than in control patients (18.7 min).",Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1334687/),min,18.7,185053,DB01226,Mivacurium
,11575530,train-of-four ratio,A train-of-four ratio of 0.75 was reached 469 min after the injection of mivacurium.,Response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene: genotyping by sequencing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11575530/),,0.75,202176,DB01226,Mivacurium
,11575530,terminal elimination half-lives,"The terminal elimination half-lives of the mivacurium isomers, cis-trans and trans-trans, were 90 min.",Response to mivacurium in a patient compound heterozygous for a novel and a known silent mutation in the butyrylcholinesterase gene: genotyping by sequencing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11575530/),min,90,202177,DB01226,Mivacurium
,15717705,k(ip),"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),1/[min],0.374,211082,DB01226,Mivacurium
,15717705,k(ei),"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),1/[min],0.151,211083,DB01226,Mivacurium
,15717705,EC50,"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),[μg] / [l],98,211084,DB01226,Mivacurium
,15717705,gamma,"Parameters (mean (percentage coefficient of variation)) of the best fitting model were: k(ip) 0.374 min(-1) (46%), k(ei) 0.151 min(-1) (36%), EC50 98 microg L(-1) (29%) and gamma 3.7 (22%).",An interstitial compartment is necessary to link the pharmacokinetics and pharmacodynamics of mivacurium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15717705/),,3.7,211085,DB01226,Mivacurium
,9840210,Cl,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),[ml] / [kg·min],19.98,217066,DB01226,Mivacurium
,9840210,Cl,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),[ml] / [kg·min],13.53,217067,DB01226,Mivacurium
,9840210,Cl,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),[ml] / [kg·min],3.47,217068,DB01226,Mivacurium
,9840210,Vdss,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),,0.29,217069,DB01226,Mivacurium
,9840210,Vdss,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),,0.24,217070,DB01226,Mivacurium
,9840210,Vdss,"Mean Cl for the cis-trans, trans-trans and cis-cis isomers were 19.98, 13.53 and 3.47 mL min(-1) kg(-1) respectively and the corresponding mean Vdss were 0.29, 0.24 and 1.00 L kg(-1).",Pharmacokinetics and pharmacodynamics of mivacurium stereoisomers in beagle dogs using twitch height and train-of-four response. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9840210/),[l] / [kg],1.00,217071,DB01226,Mivacurium
,14616318,ED50,"The estimated ED50 and ED95 were 24 and 69 microg kg-1, respectively.",Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),[μg] / [kg],24,219040,DB01226,Mivacurium
,14616318,ED95,"The estimated ED50 and ED95 were 24 and 69 microg kg-1, respectively.",Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),[μg] / [kg],69,219041,DB01226,Mivacurium
,14616318,infusion rate,The median (range) infusion rate was 3.7 microg kg-1 min-1 (1.2-2.9) and the time to a TOF ratio of 0.7 was 29.8 min (16.1-44.8).,Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),[μg] / [kg·min],3.7,219042,DB01226,Mivacurium
,14616318,time to a TOF ratio,The median (range) infusion rate was 3.7 microg kg-1 min-1 (1.2-2.9) and the time to a TOF ratio of 0.7 was 29.8 min (16.1-44.8).,Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),,0.7,219043,DB01226,Mivacurium
,14616318,time to a TOF ratio,The median (range) infusion rate was 3.7 microg kg-1 min-1 (1.2-2.9) and the time to a TOF ratio of 0.7 was 29.8 min (16.1-44.8).,Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),min,29.8,219044,DB01226,Mivacurium
,14616318,clearances,"The median clearances of the cis-cis, cis-trans and trans-trans isomers were 3.7, 29 and 28 ml kg-1 min-1, respectively.",Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),[ml] / [kg·min],3.7,219045,DB01226,Mivacurium
,14616318,clearances,"The median clearances of the cis-cis, cis-trans and trans-trans isomers were 3.7, 29 and 28 ml kg-1 min-1, respectively.",Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),[ml] / [kg·min],29,219046,DB01226,Mivacurium
,14616318,clearances,"The median clearances of the cis-cis, cis-trans and trans-trans isomers were 3.7, 29 and 28 ml kg-1 min-1, respectively.",Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),[ml] / [kg·min],28,219047,DB01226,Mivacurium
,14616318,elimination half-lives,"The elimination half-lives of the isomers were 45, 6.7 and 6.3 min, respectively.",Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),min,45,219048,DB01226,Mivacurium
,14616318,elimination half-lives,"The elimination half-lives of the isomers were 45, 6.7 and 6.3 min, respectively.",Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),min,6.7,219049,DB01226,Mivacurium
,14616318,elimination half-lives,"The elimination half-lives of the isomers were 45, 6.7 and 6.3 min, respectively.",Pharmacokinetics and pharmacodynamics of mivacurium in patients phenotypically heterozygous for the usual and atypical plasma cholinesterase variants (UA). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14616318/),min,6.3,219050,DB01226,Mivacurium
,12717125,clearances,"The clearances of the two most active isomers (Cis-Trans and Trans-Trans) were lower in the pancuronium-mivacurium group (17.6 +/- 5.1, 14.7 +/- 5.3 ml.",Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12717125/),ml,17.6,224536,DB01226,Mivacurium
,12717125,clearances,"The clearances of the two most active isomers (Cis-Trans and Trans-Trans) were lower in the pancuronium-mivacurium group (17.6 +/- 5.1, 14.7 +/- 5.3 ml.",Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12717125/),ml,14.7,224537,DB01226,Mivacurium
,9743409,onset time,"Inhibition of plasma cholinesterase activity (by 93% and 89%, respectively) increased the onset time of suxamethonium from a median of 40 s (range, 20-45 s) to 131 s (range, 114-166 s; P = 0.009) and of mivacurium from a median of 52 s (range, 40-59 s) to 105 s (range, 90-125 s; P = 0.009).",Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743409/),s,40,234253,DB01226,Mivacurium
,9743409,onset time,"Inhibition of plasma cholinesterase activity (by 93% and 89%, respectively) increased the onset time of suxamethonium from a median of 40 s (range, 20-45 s) to 131 s (range, 114-166 s; P = 0.009) and of mivacurium from a median of 52 s (range, 40-59 s) to 105 s (range, 90-125 s; P = 0.009).",Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743409/),s,131,234254,DB01226,Mivacurium
,9743409,onset time,"Inhibition of plasma cholinesterase activity (by 93% and 89%, respectively) increased the onset time of suxamethonium from a median of 40 s (range, 20-45 s) to 131 s (range, 114-166 s; P = 0.009) and of mivacurium from a median of 52 s (range, 40-59 s) to 105 s (range, 90-125 s; P = 0.009).",Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743409/),s,52,234255,DB01226,Mivacurium
,9743409,onset time,"Inhibition of plasma cholinesterase activity (by 93% and 89%, respectively) increased the onset time of suxamethonium from a median of 40 s (range, 20-45 s) to 131 s (range, 114-166 s; P = 0.009) and of mivacurium from a median of 52 s (range, 40-59 s) to 105 s (range, 90-125 s; P = 0.009).",Inhibition of the enzymic degradation of suxamethonium and mivacurium increases the onset time of submaximal neuromuscular block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743409/),s,105,234256,DB01226,Mivacurium
,10223167,clearance,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.16,240354,DB01226,Mivacurium
,10223167,elimination half-life,It has a low clearance (0.16 L/h/kg) and long elimination half-life (120 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,120,240355,DB01226,Mivacurium
,10223167,clearance,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.27,240356,DB01226,Mivacurium
,10223167,elimination half-life,"Its clearance (0.27 L/h/kg) is intermediate between those of pipecuronium and rapacuronium, but its elimination half-life is long (83 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,83,240357,DB01226,Mivacurium
,10223167,clearance,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.59,240358,DB01226,Mivacurium
,10223167,elimination half-life,It has a high clearance (0.59 L/h/kg) but a long elimination half-life (112 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,112,240359,DB01226,Mivacurium
,10223167,clearance,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.15,240360,DB01226,Mivacurium
,10223167,elimination half-life,"In adults, it has a low clearance (0.15 L/h/kg) and long elimination half-life (87 minutes).",Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,87,240361,DB01226,Mivacurium
,10223167,clearance,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],4.74,240362,DB01226,Mivacurium
,10223167,elimination half-lives,The 2 active isomers (cis-trans and trans-trans) have a high clearance (4.74 L/h/kg) and very short elimination half-lives (approximately 2 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,2,240363,DB01226,Mivacurium
,10223167,clearance,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),[l] / [h·kg],0.3,240364,DB01226,Mivacurium
,10223167,elimination half-life,Cisatracurium has an intermediate clearance (0.3 L/h/kg) and short elimination half-life (26 minutes).,Clinical pharmacokinetics of the newer neuromuscular blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10223167/),min,26,240365,DB01226,Mivacurium
,7826789,Clearance,Clearance of the cis-trans and trans-trans isomers was reduced significantly in the cirrhotic compared with the healthy group: cis-trans (median (range)) 44 (15-121) ml kg-1 min-1 vs 95 (57-213) ml kg-1 min-1 (P < 0.05); trans-trans 32 (12-64) ml kg-1 min-1 vs 70 (34-101) ml kg-1 min-1 (P < 0.05).,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],44,258563,DB01226,Mivacurium
,7826789,Clearance,Clearance of the cis-trans and trans-trans isomers was reduced significantly in the cirrhotic compared with the healthy group: cis-trans (median (range)) 44 (15-121) ml kg-1 min-1 vs 95 (57-213) ml kg-1 min-1 (P < 0.05); trans-trans 32 (12-64) ml kg-1 min-1 vs 70 (34-101) ml kg-1 min-1 (P < 0.05).,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],95,258564,DB01226,Mivacurium
,7826789,Clearance,Clearance of the cis-trans and trans-trans isomers was reduced significantly in the cirrhotic compared with the healthy group: cis-trans (median (range)) 44 (15-121) ml kg-1 min-1 vs 95 (57-213) ml kg-1 min-1 (P < 0.05); trans-trans 32 (12-64) ml kg-1 min-1 vs 70 (34-101) ml kg-1 min-1 (P < 0.05).,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],32,258565,DB01226,Mivacurium
,7826789,Clearance,Clearance of the cis-trans and trans-trans isomers was reduced significantly in the cirrhotic compared with the healthy group: cis-trans (median (range)) 44 (15-121) ml kg-1 min-1 vs 95 (57-213) ml kg-1 min-1 (P < 0.05); trans-trans 32 (12-64) ml kg-1 min-1 vs 70 (34-101) ml kg-1 min-1 (P < 0.05).,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],70,258566,DB01226,Mivacurium
,7826789,clearance,The difference in the clearance of the cis-cis isomer in the cirrhotic (4.2 (2.9-12.1) ml kg-1 min-1) compared with the healthy group (5.2 (2.9-8.9) ml kg-1 min-1) was not significant with this sample size.,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],4.2,258567,DB01226,Mivacurium
,7826789,clearance,The difference in the clearance of the cis-cis isomer in the cirrhotic (4.2 (2.9-12.1) ml kg-1 min-1) compared with the healthy group (5.2 (2.9-8.9) ml kg-1 min-1) was not significant with this sample size.,Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7826789/),[ml] / [kg·min],5.2,258568,DB01226,Mivacurium
,7618663,recovery times from maximum block to 50% recovery,"In these experiments, the recovery times from maximum block to 50% recovery of control twitch height were significantly longer with mivacurium than with atracurium (mean 25.2(SD 4.7) versus 22.6(3.1) min, p < 0.01).",Discrepancy of recovery times related to potency between atracurium and mivacurium simultaneously administered in isolated forearms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618663/),min,25.2,271654,DB01226,Mivacurium
,7618663,recovery times from maximum block to 50% recovery,"In these experiments, the recovery times from maximum block to 50% recovery of control twitch height were significantly longer with mivacurium than with atracurium (mean 25.2(SD 4.7) versus 22.6(3.1) min, p < 0.01).",Discrepancy of recovery times related to potency between atracurium and mivacurium simultaneously administered in isolated forearms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7618663/),min,22.6,271655,DB01226,Mivacurium
